[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jitendra  Wadhane C.A., CPA", "age": 43, "title": "Chief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 60, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shui  He Ph.D.", "title": "Head of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hongwei  Wang M.D., Ph.D.", "title": "Head of ADC Development & Clinical Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 10, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.13, "open": 1.15, "dayLow": 1.13, "dayHigh": 1.25, "regularMarketPreviousClose": 1.13, "regularMarketOpen": 1.15, "regularMarketDayLow": 1.13, "regularMarketDayHigh": 1.25, "payoutRatio": 0.0, "forwardPE": -1.0336134, "volume": 673225, "regularMarketVolume": 673225, "averageVolume": 492888, "averageVolume10days": 353350, "averageDailyVolume10Day": 353350, "bid": 0.9, "ask": 1.45, "bidSize": 2, "askSize": 2, "marketCap": 76195672, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": 27.019741, "fiftyDayAverage": 1.1697, "twoHundredDayAverage": 1.5348, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 6800306, "profitMargins": 0.0, "floatShares": 41153374, "sharesOutstanding": 61947700, "sharesShort": 4695721, "sharesShortPriorMonth": 5064919, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0758, "heldPercentInsiders": 0.23386, "heldPercentInstitutions": 0.33748, "shortRatio": 11.28, "shortPercentOfFloat": 0.091800004, "impliedSharesOutstanding": 61947700, "bookValue": 1.413, "priceToBook": 0.87048835, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -96286000, "trailingEps": -1.59, "forwardEps": -1.19, "enterpriseToRevenue": 2.411, "enterpriseToEbitda": -0.084, "52WeekChange": -0.660221, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 1.23, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.2, "targetMedianPrice": 6.0, "recommendationMean": 1.57143, "recommendationKey": "buy", "numberOfAnalystOpinions": 5, "totalCash": 88944000, "totalCashPerShare": 1.434, "ebitda": -80537000, "totalDebt": 19462000, "quickRatio": 5.201, "currentRatio": 5.654, "totalRevenue": 2820000, "debtToEquity": 22.206, "revenuePerShare": 0.046, "returnOnAssets": -0.31252, "returnOnEquity": -0.74804, "grossProfits": 2820000, "freeCashflow": -41649624, "operatingCashflow": -73753000, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -6.76099, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1755296021, "regularMarketTime": 1755288000, "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 8.84956, "regularMarketPrice": 1.23, "marketState": "CLOSED", "shortName": "Pyxis Oncology, Inc.", "postMarketChangePercent": -1.62601, "postMarketPrice": 1.21, "postMarketChange": -0.02, "regularMarketChange": 0.1, "regularMarketDayRange": "1.13 - 1.25", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 492888, "fiftyTwoWeekLowChange": 0.397, "fiftyTwoWeekLowChangePercent": 0.47659066, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -4.16, "fiftyTwoWeekHighChangePercent": -0.7717996, "fiftyTwoWeekChangePercent": -66.022095, "earningsTimestampStart": 1762891200, "earningsTimestampEnd": 1762891200, "isEarningsDateEstimate": true, "longName": "Pyxis Oncology, Inc.", "epsTrailingTwelveMonths": -1.59, "epsForward": -1.19, "epsCurrentYear": -1.28, "priceEpsCurrentYear": -0.96093756, "fiftyDayAverageChange": 0.060299993, "fiftyDayAverageChangePercent": 0.051551674, "twoHundredDayAverageChange": -0.30480003, "twoHundredDayAverageChangePercent": -0.19859266, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]